{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-071390","form_type":"8-K","ticker":"ICU","cik":"0001831868","company_name":"SeaStar Medical Holding Corp","filed_at":"2025-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.011870+00:00","generated_at":"2026-05-21T09:57:49.417301+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"SeaStar Medical Q1 net revenue rises to $293K; net loss narrows to $3.8M","bullets":["Net product revenue ~$293K, a four-fold increase from Q4 2024's $68K.","Net loss of $3.8M ($0.44/share) vs $12.7M ($4.73/share) a year ago.","NEUTRALIZE-AKI trial 50% enrolled; interim analysis by DSMB expected Q3 2025.","Two new Breakthrough Device Designations for SCD therapy in cardiac surgery (adult & ped).","Cash $5.3M as of March 31, 2025 vs $1.8M Dec 31, 2024; $6M offering closed Jan 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-071390","json":"https://secwatch.observer/filing/0000950170-25-071390.json","markdown":"https://secwatch.observer/filing/0000950170-25-071390.md","text":"https://secwatch.observer/filing/0000950170-25-071390.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1831868/000095017025071390/0000950170-25-071390-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1831868/000095017025071390/icu-20250514.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T09:57:49.417301+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}